Published on : Aug 24, 2017
Albany, New York, August 24, 2017 - ResearchMoz.us announced the addition of a new research report to its vast repository. The research report, titled “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market,” is a detailed analysis of the strengths and weaknesses that are estimated to shape the market in the next few years. The analysts have used primary and secondary research methodologies to help the readers gain a well-researched knowledge of the undercurrents in the Asia Pacific colorectal cancer (CRC) therapeutics market.
According to the research report, the Asia Pacific colorectal cancer therapeutics market is expected to register a CAGR of 7.9% between 2016 and 2023. With this steady progress rate, the market is expected to be worth US$7.9 bn in 2023 from US$4.7 bn in 2016. The report states that about half of the diagnosed CRC cases are seen amongst patients aged above 50. Thus the consistent rise in the market will be attributable to rise in the number of geriatrics, who are susceptible to this chronic condition. Delay in seeking medical treatment has created an urgent need for new improved therapeutics. Owing to this very reason, the demand for complex treatment solutions depending on various molecular aberrations has been noted.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=1277494
The report states that Japan is likely to be the key contributor to the Asia Pacific colorectal cancer therapeutics market. Emergence of new and sophisticated therapies in the country and growing investment in research and development are expected to have a positive influence. On the other hand, the market is likely to suffer due to upcoming patent expiration, expensive therapeutics that remain unaffordable, and lack of awareness. The growth of the market is also likely to be restrained due to slow rate of development of adjuvant and neoadjuvant pipeline products, poor reimbursement policies, strong penetration of generic drugs, and incorporation of only a few immunotherapies in the overall market. However, the market could find several lucrative opportunities as healthcare reforms are on the cusp of a meaningful change in the developing countries of Asia Pacific.
The research report provides pipeline analysis to its readers. It assesses the licensing deals, stage of developments, molecular targets, and aggregate deal values. Presently, the market offers angiogenesis inhibitors such as Cyramza, Avastin, and Zaltrap for RAS-wild-type and RAS-mutant patients. On the other hand, EGFR-targeted therapies such as Erbitux and Vectibix are prescribed for patients with RAS- or KRAS-wild-type mutations. The research report also offers a valuable insight into the dominant therapies for various patient subsets. Analysts have also measured the commercial and clinical stance of these therapies and drugs in the Asia Pacific colorectal cancer therapeutics market. With a holistic analysis of the various market dynamics, the research report allows the readers to identify the various commercial opportunities present in the overall market.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]